The Intelligence Economy: Human-Led AI for Pharma’s Next Era

KEY TAKEAWAYS

•Understand why large language models are prone to hallucination in regulated healthcare environments, and what makes that risk especially acute in pharma marketing and communications.

•Discover how LiveInsight AI’s "Background Intelligence" engine autonomously monitors competitors and emerging patient conversations, surfacing insights brand teams didn’t know to ask for.

•Learn why Friedman believes pairing human judgment with AI, rather than replacing it, is the key to turning information into decision-grade intelligence.

Pharmaceutical Executive spoke with Peter Friedman, Chairman and CEO of LiveWorld, as the company marks its 30th anniversary and introduces LiveInsight AI™, a human-led, AI-powered intelligence system built for pharma and healthcare communications. Drawing on more than three decades of experience spanning Apple and LiveWorld, Friedman traces how each wave of new technology, from the cotton gin to personal computing, expanded opportunity rather than eliminating it, and argues AI is following the same pattern in what he calls the "intelligence economy."

Friedman addresses the hallucination, compliance, and trust risks that make AI adoption especially fraught in regulated healthcare environments, including the added scrutiny pharma companies face when inaccurate information reaches patients. He details how LiveInsight AI is engineered with patent-pending mechanisms designed to prevent AI from filling in missing information with fabricated data, and describes the system’s "Background Intelligence" capability, which autonomously monitors competitors and emerging patient conversations to surface insights brand teams didn’t know to look for. Throughout, he emphasizes that human judgment, not automation alone, is what turns raw data into decision-grade intelligence.

The conversation is geared toward pharma marketers, healthcare communicators, and brand teams evaluating how to responsibly bring AI into regulated workflows. Readers and viewers will come away with a clearer picture of where AI adoption in pharma can go wrong, what a human-led approach to intelligence systems looks like in practice, and what Friedman believes will separate organizations that thrive in the intelligence economy from those that fall behind.